For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

From Attackers to Allies: Engineering Cells to Quench the Autoimmune Inferno
Friday, May 31, 2024 09:15 AM - 10:15 AM  
Room 211
From FIH to Clinical Acceleration
Concurrent Session
Chair
  • Anthony Ting, PhD, Kiji Therapeutics, United States
Speakers
  • Michael Aigner, PhD, Department of Medicine 5 – Haematology and Oncology, University Hospital of Erlangen, Germany, "Manufacturing of CARs for Autoimmune
    Diseases in an Academic Setting"
  • Nathalie Belmonte, PhD, Quell Therapeutics, United Kingdom, "Development of CAR-Treg Therapies to ModulateImmune Responses in Transplantation and Autoimmunity"
  • Peter Maag, PhD, Kyverna Therapeutics, United States, "Harnessing the Power of CAR T-Cell Therapy for a Paradigm Shift in Autoimmune Disease"
Join us for an insightful exploration into the use of CAR-T and regulatory T cells (Tregs) in treating autoimmune diseases. The session will highlight recent clinical progress with CAR-T cells, specifically targeting and modulating B-cells. Additionally, we'll delve into the role of Treg cells as a strategy for modulating immune responses. As we navigate these exciting clinical advancements, our discussions will also consider the evolving landscape of commercialization in autoimmune disease therapies, exploring pathways to bring these innovations to market and provide tangible solutions for individuals facing autoimmune challenges. 
Tony Ting
CSO
 Kiji Therapeutics
 Chair
Michael Aigner
Head of GMP Unit
 UK Erlangen
 Speaker
Nathalie Belmonte
VP Research & Product Development
 Quell Therapeutics
 Speaker
Peter Maag
CEO
 Kyverna Therapeutics
 Speaker